Zacks Research Predicts Aethlon Medical Q1 Earnings

Aethlon Medical, Inc. (NASDAQ:AEMD) – Analysts at Zacks Research issued their Q1 2027 earnings per share (EPS) estimates for shares of Aethlon Medical in a research note issued on Thursday, June 11th. Zacks Research analyst M. Marin expects that the medical equipment provider will post earnings per share of ($0.81) for the quarter. The consensus estimate for Aethlon Medical’s current full-year earnings is ($0.98) per share. Zacks Research also issued estimates for Aethlon Medical’s Q2 2027 earnings at ($0.81) EPS, Q3 2027 earnings at ($0.81) EPS, Q4 2027 earnings at ($0.81) EPS and FY2027 earnings at ($3.23) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research note on Monday, April 20th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce”.

Aethlon Medical Price Performance

NASDAQ:AEMD opened at $2.00 on Tuesday. The firm has a market capitalization of $3.14 million, a price-to-earnings ratio of -0.14 and a beta of 1.49. Aethlon Medical has a 1 year low of $1.36 and a 1 year high of $27.40. The business has a 50 day simple moving average of $2.21 and a 200-day simple moving average of $2.45.

Hedge Funds Weigh In On Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC acquired a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent SEC filing. Hedge funds and other institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.